Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2043

Sort by

Sort Order Select

Journal Articles

Hydroxyurea does not affect the spermatogonial pool in prepubertal patients with sickle cell disease

Blood (2021) 137 (6): 856–859.

https://doi.org/10.1182/blood.2020008146

Published: 2021

Includes: Supplemental data

Journal Articles

Hydroxyurea: coming to conclusions on safety

David C. Rees

Blood (2021) 137 (6): 728–729.

https://doi.org/10.1182/blood.2020008803

Published: 2021

Journal Articles

There’s safety in numbers

Russell E. Ware, Stephen D. Dertinger

Blood (2021) 137 (6): 729–731.

https://doi.org/10.1182/blood.2020010033

Published: 2021

Journal Articles

Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease

L. Joseph, C. Jean, S. Manceau, C. Chalas, C. Arnaud, A. Kamdem, C. Pondarré, A. Habibi, F. Bernaudin, S. Allali, M. de Montalembert, B. Boutonnat-Faucher, J.-B. Arlet, B. Koehl, M. Cavazzana, J.-A. Ribeil, F. Lionnet, I. Berthaut, V. Brousse

Blood (2021) 137 (6): 826–829.

https://doi.org/10.1182/blood.2020006270

Published: 2021

Journal Articles

Plasma microparticles of sickle patients during crisis or taking hydroxyurea modify endothelium inflammatory properties

Yohann Garnier, Séverine Ferdinand, Marie Garnier, Kizzy-Clara Cita, Régine Hierso, Aurélie Claes, Philippe Connes, Marie-Dominique Hardy-Dessources, Claudine Lapouméroulie, Nathalie Lemonne, Maryse Etienne-Julan, Wassim El Nemer, Marc Romana

Blood (2020) 136 (2): 247–256.

https://doi.org/10.1182/blood.2020004853

Published: 2020

Includes: Supplemental data

Journal Articles

Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic

Robert Sheppard Nickel, Stefanie Margulies, Brittany Frazer, Naomi L. C. Luban, Jennifer Webb

Blood (2020) 135 (25): 2320–2322.

https://doi.org/10.1182/blood.2020006582

Published: 2020

Journal Articles

Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic

Michael R. DeBaun

Blood (2020) 135 (22): 1997–1999.

https://doi.org/10.1182/blood.2020005992

Published: 2020

Journal Articles

The double-edged sword of AlloHCT for SCD

Adetola A. Kassim

Blood (2020) 135 (14): 1083–1085.

https://doi.org/10.1182/blood.2020005118

Published: 2020

Journal Articles

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Jennifer M. O’Sullivan, Angela Hamblin, Christina Yap, Sonia Fox, Rebecca Boucher, Anesh Panchal, Samah Alimam, Helene Dreau, Kieran Howard, Pauline Ware, Nicholas C. P. Cross, Mary Frances McMullin, Claire N. Harrison, Adam J. Mead

Blood (2019) 134 (23): 2107–2111.

https://doi.org/10.1182/blood.2019001861

Published: 2019

Includes: Supplemental data

Journal Articles

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Erica B. Esrick, MD, Maureen Achebe, MD MPH, Myriam Armant, PhD, Pablo Bartolucci, MD PhD, Marioara Felicia Ciuculescu, MD, Heather Daley, Colleen Dansereau, MSN, RN, CPN, Giuseppe Di Caprio, PhD, Bronner Goncalves, MD PhD, Nicolas Hebert, Matthew M Heeney, MD, John M. Higgins, MD PhD, Leslie E. Lehmann, MD, John P Manis, MD, Olivier Negre, PhD, Sarah Nikiforow, MD PhD, Ethan Schonbrun, PhD, David K. Wood, PhD, David A. Williams, MD

Blood (2019) 134 (Supplement_2): LBA-5.

https://doi.org/10.1182/blood-2019-132745

Published: 2019

Journal Articles

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A. Strickland, MD, Roland B. Walter, MD PhD MS, Ilaria Valimberti, Alessia Tagliavini, Paolo Mazzei, Caterina Fiesoli, Simona Scartoni, Daniela Bellarosa, Monica Binaschi, PhD, Pawel Chrom, MD PhD, Simone Baldini, MD, Krzysztof Brzózka, PhD, Angela Capriati, Andrea Pellacani, PhD MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 3920.

https://doi.org/10.1182/blood-2019-125878

Published: 2019

Journal Articles

Vitamin D and Inflammatory Markers in Children with Sickle Cell Disease

Margaret T. Lee, MD, Adiba Ashrafi, MS, Mady Hornig, MA, MD, Amelia Boehme, PhD MSPH, Nancy S. Green, MD, Gary M. Brittenham, MD

Blood (2019) 134 (Supplement_1): 2312.

https://doi.org/10.1182/blood-2019-129771

Published: 2019

Journal Articles

Fetal Hemoglobin Promotes P. Falciparum Growth in Sickle Cell Disease Erythrocytes

Natasha M. Archer, MD, Manoj Duraisingh

Blood (2019) 134 (Supplement_1): 2252.

https://doi.org/10.1182/blood-2019-130763

Published: 2019

Journal Articles

Targeting Transcriptional Co-Activator PGC-1a for the Treatment of Sickle Cell Disease

Alawi Habara, MBBS, MSc, Cuong LE, PhD, David H.K. Chui, MD, Martin H. Steinberg, MD, Shuaiying Cui, PhD

Blood (2019) 134 (Supplement_1): 2254.

https://doi.org/10.1182/blood-2019-123959

Published: 2019

Journal Articles

Stroke Avoidance for Children in República Dominicana (SACRED):a Prospective Trial to Reduce Stroke in Children with Sickle Cell Anemia

Luisanna Sanchez, MD, Rosa M. Nieves, MD, Teresa S. Latham, MA, Adam Lane, PhD, Neelum Jeste, MD, Gabriela S. Urcuyo, MD, Melissa E. Berges, MD, Carla Florencio, MD, Carla Gonzalez, MD, Paola Del Villar, MD, Janet Adams, Susan Stuber, MA, William Schultz, M.H.S., Rafael Mena, MD, Russell E. Ware, MD PhD

Blood (2019) 134 (Supplement_1): 2285.

https://doi.org/10.1182/blood-2019-130214

Published: 2019

Journal Articles

Assessing Efficacy of Provider and Family Education, Electronic Health Record Documentation Tools, and Information Technology to Increase Use of Hydroxyurea in Children with Sickle Cell Anemia

Kyle Hickman, MD, Steve McCalley, BSN, RN-BC, Vinay Vaidya, MD, Esteban Gomez, MD, Christine M. Knoll, MD, Joanna L. Gendreau, DO, Lori Wagner, MSN, FNP-C, Meenakshi Goyal-Khemka, MD, Brooke Cook, BSN, RN, Kelli Fischbeck, BSN, RN, Sanjay J. Shah, MBBS

Blood (2019) 134 (Supplement_1): 2288.

https://doi.org/10.1182/blood-2019-127770

Published: 2019

Journal Articles

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study

Kenneth I. Ataga, MD, Abdullah Kutlar, MD, Laurie DeBonnett, MD, Jeremie Lincy, Julie Kanter, MD

Blood (2019) 134 (Supplement_1): 2289.

https://doi.org/10.1182/blood-2019-125868

Published: 2019

Journal Articles

Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Satheesh Chonat, MD, Earl Fields, Hannah Baratz, Amanda Watt, Mira Pochron, PhD, Sandy Dixon, Margaret Tonda, PharmD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Clark Brown, MD PhD, David R. Archer, PhD

Blood (2019) 134 (Supplement_1): 2281.

https://doi.org/10.1182/blood-2019-129351

Published: 2019

Journal Articles

Barriers to the Use of Endari™ in an Urban Adult Sickle Cell Center

Ugochi Olivia Ogu, MD, Merin Thomas, NP, Florence Chan, PharmD, Gracy Sebastian, NP, Caterina P. Minniti, MD

Blood (2019) 134 (Supplement_1): 2287.

https://doi.org/10.1182/blood-2019-126666

Published: 2019

Journal Articles

Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium

Julie Kanter, MD, Mary Dooley, MS, Logan P Sirline, MPH, Martina Mueller, PhD, Shannon Phillips, PhD RN, Alyssa M Schlenz, PhD, Cathy Melvin, PhD MPH, Robert J. Adams, MD MS

Blood (2019) 134 (Supplement_1): 2270.

https://doi.org/10.1182/blood-2019-129951

Published: 2019

NARROW

Hydroxyurea does not affect the spermatogonial pool in prepubertal patients with sickle cell disease

Hydroxyurea: coming to conclusions on safety

There’s safety in numbers

Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease

Plasma microparticles of sickle patients during crisis or taking hydroxyurea modify endothelium inflammatory properties

Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic

Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic

The double-edged sword of AlloHCT for SCD

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Vitamin D and Inflammatory Markers in Children with Sickle Cell Disease

Fetal Hemoglobin Promotes P. Falciparum Growth in Sickle Cell Disease Erythrocytes

Targeting Transcriptional Co-Activator PGC-1a for the Treatment of Sickle Cell Disease

Stroke Avoidance for Children in República Dominicana (SACRED):a Prospective Trial to Reduce Stroke in Children with Sickle Cell Anemia

Assessing Efficacy of Provider and Family Education, Electronic Health Record Documentation Tools, and Information Technology to Increase Use of Hydroxyurea in Children with Sickle Cell Anemia

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study

Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Barriers to the Use of Endari™ in an Urban Adult Sickle Cell Center

Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only